Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.33)
# 2,566
Out of 4,761 analysts
102
Total ratings
45.28%
Success rate
-0.2%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MCK McKesson | Maintains: Outperform | $650 → $675 | $597.71 | +12.93% | 5 | Feb 6, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $240 → $260 | $190.43 | +36.53% | 12 | Feb 6, 2025 | |
| CVS CVS Health | Maintains: Outperform | $60 → $65 | $63.48 | +2.39% | 6 | Jan 27, 2025 | |
| WBA Walgreens Boots Alliance | Maintains: In-Line | $9 → $12 | $10.16 | +18.11% | 13 | Jan 13, 2025 | |
| LH Labcorp Holdings | Upgrades: Outperform | $260 → $265 | $249.85 | +6.06% | 4 | Jan 7, 2025 | |
| XRAY DENTSPLY SIRONA | Downgrades: In-Line | $20 | $18.75 | +6.67% | 7 | Jan 7, 2025 | |
| CAH Cardinal Health | Upgrades: Outperform | $140 | $127.06 | +10.18% | 6 | Jan 7, 2025 | |
| WAY Waystar Holding | Maintains: Outperform | $32 → $36 | $42.21 | -14.71% | 4 | Nov 7, 2024 | |
| TDOC Teladoc Health | Maintains: In-Line | $8 → $9 | $11.51 | -21.81% | 2 | Oct 8, 2024 | |
| IQV IQVIA Holdings | Maintains: Outperform | $270 → $265 | $191.04 | +38.71% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $10 | $5.23 | +91.20% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $22 → $20 | $14.88 | +34.41% | 6 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $34 → $45 | $72.37 | -37.82% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $4 | $3.52 | +13.64% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $23 | $20.87 | +10.21% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: In-Line | $165 | $172.24 | -4.20% | 2 | Aug 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $24.52 | -18.43% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $17.94 | +46.32% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $10.05 | +49.25% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $4.57 | +140.70% | 2 | Jan 4, 2022 |
McKesson
Feb 6, 2025
Maintains: Outperform
Price Target: $650 → $675
Current: $597.71
Upside: +12.93%
Align Technology
Feb 6, 2025
Maintains: Outperform
Price Target: $240 → $260
Current: $190.43
Upside: +36.53%
CVS Health
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $63.48
Upside: +2.39%
Walgreens Boots Alliance
Jan 13, 2025
Maintains: In-Line
Price Target: $9 → $12
Current: $10.16
Upside: +18.11%
Labcorp Holdings
Jan 7, 2025
Upgrades: Outperform
Price Target: $260 → $265
Current: $249.85
Upside: +6.06%
DENTSPLY SIRONA
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $18.75
Upside: +6.67%
Cardinal Health
Jan 7, 2025
Upgrades: Outperform
Price Target: $140
Current: $127.06
Upside: +10.18%
Waystar Holding
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $42.21
Upside: -14.71%
Teladoc Health
Oct 8, 2024
Maintains: In-Line
Price Target: $8 → $9
Current: $11.51
Upside: -21.81%
IQVIA Holdings
Oct 8, 2024
Maintains: Outperform
Price Target: $270 → $265
Current: $191.04
Upside: +38.71%
Oct 8, 2024
Maintains: Outperform
Price Target: $8 → $10
Current: $5.23
Upside: +91.20%
Oct 8, 2024
Maintains: In-Line
Price Target: $22 → $20
Current: $14.88
Upside: +34.41%
Oct 8, 2024
Maintains: In-Line
Price Target: $34 → $45
Current: $72.37
Upside: -37.82%
Oct 8, 2024
Maintains: In-Line
Price Target: $7 → $4
Current: $3.52
Upside: +13.64%
Sep 23, 2024
Maintains: Outperform
Price Target: $18 → $23
Current: $20.87
Upside: +10.21%
Aug 28, 2024
Reinstates: In-Line
Price Target: $165
Current: $172.24
Upside: -4.20%
Jul 9, 2024
Maintains: Outperform
Price Target: $23 → $20
Current: $24.52
Upside: -18.43%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $17.94
Upside: +46.32%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $10.05
Upside: +49.25%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $4.57
Upside: +140.70%